Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Mind Medicine (MindMed) Inc. - Common Shares
(NQ:
MNMD
)
15.02
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mind Medicine (MindMed) Inc. - Common Shares
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Another Psychedelic Stock Debuts, As This One Sets Up In A Base
↗
July 29, 2021
Field Trip Health dipped in its first day on the Nasdaq, making it the latest psychedelics company to hit a big U.S. exchange.
Via
Investor's Business Daily
MindMed Leverages Ayahuasca's Ingredient DMT In Psychedelic-Inspired Therapies, Launches Trials With 30 Subjects
↗
July 29, 2021
Psychoactive brew ayahuasca is known for having a fast-onset antidepressant effect. With serotonergic psychedelics, such...
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
↗
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"
↗
July 23, 2021
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday,
Via
Benzinga
Mind Medicine Has More Obstacles Than Opportunities
↗
July 20, 2021
MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business.
Via
InvestorPlace
Psyched: Numinus, MindMed, Cybin Reach Milestones, Harvard To Study Psychedelics Law, Michael Pollan Dives Into Mescaline
↗
July 12, 2021
Michael Pollan’s New Book Takes A Deep Dive Into Mescaline – Will This Be A Turning Point For The Recognition And Study of&n...
Via
Benzinga
How To Invest In "Magic Mushrooms" (Psychedelics)
↗
July 09, 2021
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.
Via
Talk Markets
MindMed Stock Is Overvalued and Too Risky to Own
↗
July 08, 2021
MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about.
Via
InvestorPlace
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
↗
July 07, 2021
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps...
Via
Benzinga
The 6 Leading Psychedelic Stocks In Drug R&D
↗
July 07, 2021
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D...
Via
Talk Markets
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
↗
July 02, 2021
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o...
Via
Benzinga
The MindMed Psychedelic Revolution Will Take Years to Come to Fruition
↗
July 02, 2021
MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants.
Via
InvestorPlace
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
↗
June 30, 2021
Institutional analysts are taking a liking to the industry ...
Via
Benzinga
Video: Talking Cannabis With Aurora Co-Founder Terry Booth | Benzinga Cannabis Insider 6/29
↗
June 30, 2021
Benzinga’s
Via
Benzinga
Topics
Cannabis
Get a Dose of Innovative Science With Mind Medicine
↗
June 29, 2021
MNMD stock ran high last year, but the story is still being written as Mind Medicine marks progress with its psychedelics-based treatments.
Via
InvestorPlace
Psychedelics-Focused MindMed Joins FTSE Russell 3000 Index, 'A True Honor'
↗
June 29, 2021
A psychedelics-focused medicine company MindMed (NASDAQ:
Via
Benzinga
Pandemic Fallout: 6 Mental Health Stocks To Watch
↗
June 28, 2021
One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next globa...
Via
Benzinga
MindMed Can Play a Big Role in the Growing Mental Wellness Industry
↗
June 28, 2021
With Covid-19 increasing the frequency of mental health problems, MNMD stock is a way to invest in psychedelics, which are seeing legitimacy.
Via
InvestorPlace
Why This MindMed Analyst Is Bullish: 'One Of The Most Diverse Pipelines In Psychedelics'
↗
June 28, 2021
Mind Medicine (MindMed) Inc (NASDAQ:MNMD) shares traded hi...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021
↗
June 28, 2021
Upgrades For Toll Brothers Inc (NYSE:
Via
Benzinga
Cannabis Movers & Shakers: HempFusion, Decibel, ARCA, Love Hemp, MindMed, Halo
↗
June 25, 2021
HempFusion Wellness Promotes VP And Controller Maria Leal To Interim CFO HempFusion Wellness Inc. (TSX:
Via
Benzinga
Topics
Cannabis
Atai IPO Day An Underwhelming Event
↗
June 21, 2021
The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations.
Via
Talk Markets
Topics
Initial Public Offering
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
↗
June 21, 2021
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq...
Via
Benzinga
Topics
Artificial Intelligence
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
↗
June 18, 2021
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the...
Via
Benzinga
New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End
↗
June 18, 2021
Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, after an upsized offering for the Atai IPO.
Via
Investor's Business Daily
Topics
Initial Public Offering
Is Mind Medicine a Buy?
↗
June 17, 2021
It offers a great way to tap into the psychedelics market -- but is it too risky of an investment right now?
Via
The Motley Fool
Topics
Cannabis
Could Mind Medicine Be a Millionaire-Maker Stock?
↗
June 16, 2021
Yes, but with the chance of great reward comes substantial risk.
Via
The Motley Fool
Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers
↗
June 14, 2021
Atai Launches $214 Million Nasdaq IPO Offering Psychedelics biotech platform Atai life Sciences has announced an initi...
Via
Benzinga
Topics
Initial Public Offering
Mind Medicine Stock Might Still Be Worth the Risk Here
↗
June 11, 2021
The rampant addiction crisis in America requires a new effective solution, which may suit MNMD stock well.
Via
InvestorPlace
EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO
↗
June 10, 2021
Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a biotech company focused on the field of psychedelics, formally announced this week that J.R. Rahn, the company’s co...
Via
Benzinga
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today